Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Broad-spectrum matrix metalloproteinase (MMP) inhibitors (MMPI) were unsuccessful in cancer clinical trials, partly due to side effects resulting from limited knowledge of the full repertoire of MMP substrates, termed the substrate degradome, and hence the in vivo functions of MMPs. To gain further insight into the degradome of MMP-14 (membrane type 1 MMP) an MMPI, prinomastat (drug code AG3340), was used to reduce proteolytic processing and ectodomain shedding in human MDA-MB-231 breast cancer cells transfected with MMP-14. We report a quantitative proteomic evaluation of the targets and effects of the inhibitor in this cell-based system. Proteins in cell-conditioned medium (the secretome) and membrane fractions with levels that were modulated by the MMPI were identified by isotope-coded affinity tag (ICAT) labeling and tandem mass spectrometry. Comparisons of the expression of MMP-14 with that of a vector control resulted in increased MMP-14/vector ICAT ratios for many proteins in conditioned medium, indicating MMP-14-mediated ectodomain shedding. Following MMPI treatment, the MMPI/vehicle ICAT ratio was reversed, suggesting that MMP-14-mediated shedding of these proteins was blocked by the inhibitor. The reduction in shedding or the release of substrates from pericellular sites in the presence of the MMPI was frequently accompanied by the accumulation of the protein in the plasma membrane, as indicated by high MMPI/vehicle ICAT ratios. Considered together, this is a strong predictor of biologically relevant substrates cleaved in the cellular context that led to the identification of many undescribed MMP-14 substrates, 20 of which we validated biochemically, including DJ-1, galectin-1, Hsp90alpha, pentraxin 3, progranulin, Cyr61, peptidyl-prolyl cis-trans isomerase A, and dickkopf-1. Other proteins with altered levels, such as Kunitz-type protease inhibitor 1 and beta-2-microglobulin, were not substrates in biochemical assays, suggesting an indirect affect of the MMPI, which might be important in drug development as biomarkers or, in preclinical phases, to predict systemic drug actions and adverse side effects. Hence, this approach describes the dynamic pattern of cell membrane ectodomain shedding and its perturbation upon metalloproteinase drug treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108 · cited 1×
“The membrane type 1 matrix metalloproteinase (MMP-14) is a member of the MMP family of zinc-dependent endoproteinases that are important in cancer (31, 92), consisting of 23 members in humans, 6 of which (including MMP-14) are membrane anchored (50, 122).”
BackgroundQuantitative analysis of complex protein mixtures using isotope-coded affinity tags
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999) · Nature Biotechnology · doi:10.1038/13690 · Cited by 4,683
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Matrix metalloproteinases as modulators of inflammation and innate immunity
Parks, W. C., Wilson, C. L., & López-Boado, Y. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1418 · Cited by 1,929
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349 · cited 2×
“side effects including tendonitis and myalgia (11, 22, 92, 93, 149).”
BackgroundSelf-citationMatrix metalloproteinases: they're not just for matrix anymore!
McCawley, L. J., & Matrisian, L. M. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00248-9 · Cited by 1,274 · cited 1×
“adhesion molecules) (17, 75, 94), regulating processes involved”
BackgroundInduction of Cell Migration by Matrix Metalloprotease-2 Cleavage of Laminin-5
Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G., & Quaranta, V. (1997) · Science · doi:10.1126/science.277.5323.225 · Cited by 1,221
The Angiogenic Factor Cyr61 Activates a Genetic Program for Wound Healing in Human Skin Fibroblasts
Chen, C.-C., Mo, F.-E., & Lau, L. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107666200 · Cited by 300
Sidis, Y., Mukherjee, A., Keutmann, H., Delbaere, A., Sadatsuki, M., & Schneyer, A. (2006) · Endocrinology · doi:10.1210/en.2006-0089 · Cited by 211 · cited 1×
“Follistatin-related protein 3, which binds and masks the activities of activin, myostatin, and some bone morphogenetic proteins (119), was processed by TABLE 3.”
Method
Cited by
Biological role of matrix metalloproteinases: a critical balance
Löffek, S., Schilling, O., & Franzke, C.-W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00146510 · Cited by 756
Rodríguez, D., Morrison, C. J., & Overall, C. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.09.015 · Cited by 560
Self-citationKleifeld, O., Doucet, A., auf dem Keller, U., Prudova, A., Schilling, O., Kainthan, R. K., Starr, A. E., Foster, L. J., Kizhakkedathu, J. N., & Overall, C. M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1611 · Cited by 545
Self-citationMembrane-type matrix metalloproteinases: Their functions and regulations
Itoh, Y. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.03.004 · Cited by 401
The granulin gene family: from cancer to dementia
Bateman, A., & Bennett, H. P. J. (2009) · BioEssays · doi:10.1002/bies.200900086 · Cited by 337
Kleifeld, O., Doucet, A., Prudova, A., auf dem Keller, U., Gioia, M., Kizhakkedathu, J. N., & Overall, C. M. (2011) · Nature Protocols · doi:10.1038/nprot.2011.382 · Cited by 315
Self-citationMissing the target: matrix metalloproteinase antitargets in inflammation and cancer
Dufour, A., & Overall, C. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.02.004 · Cited by 312
Self-citationCauwe, B., & Opdenakker, G. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2010.501783 · Cited by 299
Prudova, A., auf dem Keller, U., Butler, G. S., & Overall, C. M. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m000050-mcp201 · Cited by 282
Self-citationMatrix metalloproteinase proteomics: substrates, targets, and therapy
Morrison, C. J., Butler, G. S., Rodríguez, D., & Overall, C. M. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.06.006 · Cited by 266
Self-citationProgranulin, lysosomal regulation and neurodegenerative disease
Kao, A. W., McKay, A., Singh, P. P., Brunet, A., & Huang, E. J. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.36 · Cited by 258
The lysosomal function of progranulin, a guardian against neurodegeneration
Paushter, D. H., Du, H., Feng, T., & Hu, F. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1861-8 · Cited by 230
“MMP-9a/12/14 Endopeptidase Processes PGRN into granulin peptides [18, 118, 141]”
Klein, T., Eckhard, U., Dufour, A., Solis, N., & Overall, C. M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00120 · Cited by 229
Self-citationGelatinase B/MMP-9 in Tumour Pathogenesis and Progression
Farina, A., & Mackay, A. (2014) · Cancers · doi:10.3390/cancers6010240 · Cited by 206
Matrix metalloproteinase collagenolysis in health and disease
Amar, S., Smith, L., & Fields, G. B. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.04.015 · Cited by 194
Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
“…al., 2002), as outlined earlier, and to several members of the matrix metalloproteinase family namely MMP2, MMP9, MMP13 and MMP14 and MMP17 (Liu et al., 2007; Butler et al., 2008; Suh et al., 2012), and ADAMPTS-7 (a disintegrin and metalloproteinase with thrombospondin motifs 7) (Bai et al., 2009).”
BackgroundRivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
Progranulin and Its Biological Effects in Cancer
Arechavaleta-Velasco, F., Perez-Juarez, C. E., Gerton, G. L., & Diaz-Cueto, L. (2017) · Medical Oncology · doi:10.1007/s12032-017-1054-7 · Cited by 109
Metadata
- Authors
- Butler, G. S., Dean, R. A., Tam, E. M., & Overall, C. M.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2008-08-01
- Volume
- 28
- Issue
- 15
- Pages
- 4896-4914
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2154754261
- Cited by
- 155
- References
- 10
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.